ScholarLens Back to search
2006•The Journal of Clinical PsychiatryRequires access

Clinical study of aripiprazole and risperidone in treatment of schizophrenia

Xie Pei-lian

Open publisher page 2 citations

Abstract

Objective:To evaluate the efficacy of aripiprazole in the treatment of schizophrenia.Method:Eighty hospitalized schizophrenias with a course less than 3 years were randomly divided into two groups,one was treated with aripiprazole(n=40)and the other was treated with resperidone(n=40) for 6 weeks.Both groups were administered with the positive and negative symptoms scale(PANSS),treatment emergent signs and symptoms(TESS) and rating scale for extrapyramidel side effects(RSESE) to evaluate their treatment efficacy and side reaction respectively.Results:The efficacies of both drugs in treatment of schizophrenia were similar,the occurrence of EPS in aripiprazole group was 13 cases(32.5%).It was significantly lower than that of risperidone group(22 cases,55.0%)(P0.05).Conclusion:Aripiprazole is a safe antipsychotic drug,it has good effect and good compliance.

About this research paper

What this paper is about

Objective:To evaluate the efficacy of aripiprazole in the treatment of schizophrenia.Method:Eighty hospitalized schizophrenias with a course less than 3 years were randomly divided into two groups,one was treated with aripiprazole(n=40)and the other was treated with resperidone(n=40) for 6 weeks.Both groups were administered with the positive and negative symptoms scale(PANSS),treatment emergent signs and symptoms(TESS) and rating scale for extrapyramidel side effects(RSESE) to evaluate their treatment efficacy and side reaction respectively.Results:The efficacies of both drugs in treatment of schizophrenia were similar,the occurrence of EPS in aripiprazole group was 13 cases(32.5%).It was significantly lower than that of risperidone group(22 cases,55.0%)(P0.05).Conclusion:Aripiprazole is a safe antipsychotic drug,it has good effect and good compliance.

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To evaluate the efficacy of aripiprazole in the treatment of schizophrenia.Method:Eighty hospitalized schizophrenias with a course less than 3 years were randomly divided into two groups,one was treated with aripiprazole(n=40)and the other was treated with resperidone(n=40) for 6 weeks.Both groups were administered with the positive and negative symptoms scale(PANSS),treatment emergent signs and symptoms(TESS) and rating scale for extrapyramidel side effects(RSESE) to evaluate their treatment efficacy and side reaction respectively.Results:The efficacies of both drugs in treatment of schizophrenia were similar,the occurrence of EPS in aripiprazole group was 13 cases(32.5%).It was significantly lower than that of risperidone group(22 cases,55.0%)(P0.05).Conclusion:Aripiprazole is a safe antipsychotic drug,it has good effect and good compliance.

Key concepts: Aripiprazole, Risperidone, Schizophrenia (object-oriented programming), Negative symptom, Medicine, Rating scale, Side effect (computer science), Psychology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of aripiprazole and risperidone in treatment of schizophrenia — Research Paper | ScholarLens